For ophthalmic use only. Instill drops into the conjunctival sac. Avoid touching the dropper tip to the eye or any other surface to prevent contamination. Apply gentle pressure to the nasolacrimal duct for a minute after instillation to minimize systemic absorption.

Tropicamide is an anticholinergic (muscarinic antagonist) that blocks the action of acetylcholine on the sphincter muscle of the iris and the ciliary body, leading to mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). Phenylephrine is an alpha-1 adrenergic agonist that acts on the dilator muscle of the iris, causing mydriasis without significant cycloplegia. The combination provides rapid and potent mydriasis and cycloplegia.

• •Hypersensitivity to tropicamide, phenylephrine, or any component
• •Narrow-angle or angle-closure glaucoma
• •Patients with an anterior chamber angle configuration that may predispose them to angle closure
• •Known or suspected cerebral atherosclerosis
• •Severe hypertension
• •Tachycardia
• •Ventricular fibrillation
• •Hyperthyroidism
• •Known sensitivity to adrenergic amines.

Store below 25°C. Protect from light. Do not freeze. Keep out of reach of children.

Systemic overdose symptoms may include flushing, dry skin, blurred vision, tachycardia, irregular pulse, fever, abdominal distension, convulsions, and central nervous system depression (tropicamide) or hypertension, arrhythmia, and headache (phenylephrine). Treatment is supportive and symptomatic.

Pregnancy: Category C. Use only if potential benefit justifies potential risk to the fetus. Lactation: It is not known whether components are excreted in human milk. Caution should be exercised when administered to a nursing mother.